A targeted genomic alteration analysis predicts survival of melanoma patients under BRAF inhibitors.
Louveau B, Delyon J, De Moura CR, Battistella M, Jouenne F, Golmard L, Sadoux A, Podgorniak MP, Chami I, Marco O, Caramel J, Dalle S, Feugeas JP, Dumaz N, Lebbe C, Mourah S.
Louveau B, et al.
Oncotarget. 2019 Mar 1;10(18):1669-1687. doi: 10.18632/oncotarget.26707. eCollection 2019 Mar 1.
Oncotarget. 2019.
PMID: 30899440
Free PMC article.